Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (NCT07494305)
A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Major Depressive Episodes Associated With Bipolar I Disorder
🩺 Plain-English Summary (8th-Grade Level)
Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo). Treatment is for 6 weeks.
Who can join: Review the eligibility criteria below.
Location: Pillar Clinical Research — Bentonville, Arkansas
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Pillar Clinical Research — Bentonville, Arkansas
- Pillar Clinical Research — Little Rock, Arkansas
- CenExel — Bellflower, California
- ProScience Research Group — Culver City, California
- CenExel — Garden Grove, California
- Synergy San Diego — Lemon Grove, California
- NRC Research Institute — Los Angeles, California
- NRC Research Institute — Orange, California
- CenExel — Riverside, California
- CenExel — Torrance, California
- St. Jude Clinical Research — Doral, Florida
- Cenexel Hollywood Florida — Hollywood, Florida
- Innovative Clinical Research — Miami Lakes, Florida
- Health Synergy Clinical Research — West Palm Beach, Florida
- Trialmed — Atlanta, Georgia
- Cenexel Decatur GA — Decatur, Georgia
- Pillar Clinical Research — Chicago, Illinois
- NSRT — Detroit, Michigan
- Arch Clinical Trials — St Louis, Missouri
- Redbird Research — Las Vegas, Nevada
- Manhattan Behavioral Medicine — New York, New York
- Neuro-Behavioral Clinical Research — Canton, Ohio
- Adams Clinical — Philadelphia, Pennsylvania
- Adams Clinical — DeSoto, Texas
- Pillar Clinical Research — Richardson, Texas
📞 Contact the Study Coordinator
Phone: (212) 605-0300
Email: clinicaltrials@lbpharma.us
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Bipolar I Disorder
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression — Birmingham, Alabama
- A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder — Boston, Massachusetts
- An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania — Little Rock, Arkansas
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder — Rochester, Minnesota
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder — Huntsville, Alabama
- Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder — Belmont, Massachusetts
Explore by condition: All Bipolar I Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.